story of the week
Trastuzumab Plus Capecitabine With or Without Pertuzumab in HER2-Positive Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy
J. Clin. Oncol 2017 Apr 24;[EPub Ahead of Print], A Urruticoechea, M Rizwanullah, SA Im, ACS Ruiz, I Láng, G Tomasello, H Douthwaite, T Badovinac Crnjevic, S Heeson, J Eng-Wong, M MuñozFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.